PA8624101A1 - Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina - Google Patents

Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina

Info

Publication number
PA8624101A1
PA8624101A1 PA20058624101A PA8624101A PA8624101A1 PA 8624101 A1 PA8624101 A1 PA 8624101A1 PA 20058624101 A PA20058624101 A PA 20058624101A PA 8624101 A PA8624101 A PA 8624101A PA 8624101 A1 PA8624101 A1 PA 8624101A1
Authority
PA
Panama
Prior art keywords
compounds
tetrahydroisoquinolinilo
isoquinolina
quinazolina
derivatives
Prior art date
Application number
PA20058624101A
Other languages
English (en)
Inventor
Spiros Liras
Martin Patrick Allen
Thomas Allen Chappie
Michael John Humphrey
William Michael Whalen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8624101A1 publication Critical patent/PA8624101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE QUINAZOLINA E ISOQUINOLINA SUSTITUIDOS QUE SIRVEN COMO EFICACES INHIBIDORES DE LA FOSFODIESTERASA (PDE). EN PARTICULAR, LA INVENCION SE REFIERE A DICHOS COMPUESTOS QUE SON INHIBIDORES SELECTIVOS DE LA PDE-10. LA INVENCION TAMBIEN SE REFIERE A PRODUCTOS INTERMEDIOS PARA LA PREPARACION DE DICHOS COMPUESTOS; COMPOSICIONES FARMACEUTICAS QUE COMPRENDE DICHOS COMPUESTOS Y AL USO DE DICHOS COMPUESTOS EN UN PROCEDIMIENTO PARA TRATAR CIERTOS TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL (SNC) U OTROS.
PA20058624101A 2004-02-18 2005-02-18 Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina PA8624101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54556504P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
PA8624101A1 true PA8624101A1 (es) 2005-11-25

Family

ID=34910729

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058624101A PA8624101A1 (es) 2004-02-18 2005-02-18 Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina

Country Status (14)

Country Link
US (1) US7268142B2 (es)
EP (1) EP1723134A2 (es)
JP (1) JP2007523152A (es)
AR (1) AR047682A1 (es)
BR (1) BRPI0507839A (es)
CA (1) CA2556413A1 (es)
DO (1) DOP2005000022A (es)
GT (1) GT200500027A (es)
NL (1) NL1028321C2 (es)
PA (1) PA8624101A1 (es)
PE (1) PE20050694A1 (es)
TW (1) TW200528446A (es)
UY (1) UY28750A1 (es)
WO (1) WO2005082883A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
CA2619462A1 (en) * 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
JP2009527542A (ja) * 2006-02-23 2009-07-30 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害薬としての置換キナゾリン
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2007103554A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
EP2057153B1 (en) * 2006-07-10 2012-09-12 H. Lundbeck A/S (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7- dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
US7786139B2 (en) 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
MX2009012474A (es) * 2007-05-18 2009-12-18 Wyeth Corp Compuestos de quinazolina.
US7858620B2 (en) 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
UA102693C2 (ru) * 2008-06-20 2013-08-12 Х. Луннбек А/С Производные фенилимидазола как ингибиторы фермента pde10a
US8133897B2 (en) 2008-06-20 2012-03-13 H. Lundbeck A/S Phenylimidazole derivatives as PDE10A enzyme inhibitors
CA2760837C (en) * 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8815894B2 (en) * 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
TW201200516A (en) 2009-12-17 2012-01-01 Lundbeck & Co As H Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
TWI487705B (zh) 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
AU2011221075B2 (en) 2010-02-26 2013-12-19 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compounds and their use as PDE10 inhibitors
TW201215607A (en) 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
TW201206935A (en) 2010-07-16 2012-02-16 Lundbeck & Co As H Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor
DE102010042833B4 (de) 2010-10-22 2018-11-08 Helmholtz-Zentrum Dresden - Rossendorf E.V. Neue Halogenalkoxychinazoline, deren Herstellung und Verwendung
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
AU2012219316A1 (en) 2011-02-18 2013-10-03 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
WO2013045607A1 (en) 2011-09-30 2013-04-04 H. Lundbeck A/S Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors
WO2013050527A1 (en) 2011-10-05 2013-04-11 H. Lundbeck A/S Quinazoline derivatives as pde10a enzyme inhibitors
AR089361A1 (es) 2011-12-21 2014-08-20 Lundbeck & Co As H Derivados de quinolina como inhibidores de la enzima pde10a
WO2013127817A1 (en) 2012-02-27 2013-09-06 H. Lundbeck A/S Imidazole derivatives as pde10a enzyme inhibitors
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
KR102169426B1 (ko) 2013-02-27 2020-10-23 모찌다 세이야쿠 가부시끼가이샤 신규 피라졸 유도체
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
CA2965336A1 (en) * 2014-10-22 2016-04-28 The Board Of Regents Of The University Of Texas System Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
EP4077306A1 (en) 2019-12-18 2022-10-26 CHDI Foundation, Inc. Compounds and probes for imaging huntingtin protein
CN114456184B (zh) * 2022-02-21 2023-08-22 南华大学附属第一医院 一种3-芳基异喹啉衍生物及其制备与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674791A (en) * 1968-03-26 1972-07-04 Marion Laboratories Inc Benzamido 2 lower alkyl decahydroisoquinolines
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4

Also Published As

Publication number Publication date
US7268142B2 (en) 2007-09-11
AR047682A1 (es) 2006-02-01
CA2556413A1 (en) 2005-09-09
DOP2005000022A (es) 2005-08-30
WO2005082883A2 (en) 2005-09-09
NL1028321C2 (nl) 2006-05-23
JP2007523152A (ja) 2007-08-16
US20050182079A1 (en) 2005-08-18
NL1028321A1 (nl) 2005-08-19
EP1723134A2 (en) 2006-11-22
BRPI0507839A (pt) 2007-05-08
TW200528446A (en) 2005-09-01
UY28750A1 (es) 2005-09-30
WO2005082883A3 (en) 2007-04-26
GT200500027A (es) 2005-10-24
PE20050694A1 (es) 2005-10-04

Similar Documents

Publication Publication Date Title
PA8624101A1 (es) Derivados de tetrahidroisoquinolinilo de quinazolina e isoquinolina
SV2006002175A (es) Nuevos derivados piperidilo de quinazolina e isoquinolina ref. pc25915a
CU23780B7 (es) Compuestos de quinolina heteroaromaticos y su uso como inhibidores de pde10
CR9135A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
UY30080A1 (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
PA8675701A1 (es) Nuevos derivados del fluoreno, composiciones que los contienen y su utilización
HN2001000192A (es) Derivados de pirazol
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
DK1377586T3 (da) Tricykliske diazepiner som tocolytiske oxytocinreceptorantagonister
EP2012780A4 (en) SUBSTITUTED 1H-BENZIMIDAZOLE-4-CARBOXAMIDES AS POTENTE PARP HEMMER
HN2009000018A (es) Inhibidores de tirosina quinasa
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
GT200500332A (es) Azabenzoxazoles para el tratamiento de trastornos del snc
CL2011000832A1 (es) Compuestos derivados de tieno[2,3-d]pirimidin-4-amina sustituidos, antagonista de los receptores de adenosina a2a; composicion farmaceutica; y su uso para tratar trastornos neurodegenerativos o motores, entre otras enfermedades.
BR112018004347A2 (pt) derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida
PA8653001A1 (es) Azanbenzoxazoles para el tratamiento de los trastornos del snc
DOP2005000139A (es) Nuevos derivados piperidilo do quinazolina e isoquinolina
DE602006016430D1 (de) Phosphodiesteraseinhibitoren auf azolbasis
UY29052A1 (es) Nuevos inhibidores de la recaptación de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central
DOP2006000004A (es) Compuestos de quinolina heteroaromaticos.
DOP2005000151A (es) Nuevos inhibidores de la recaptacion de norepinefrina de quinoxalinona para el tratamiento de trastonos del sisitema nervioso central.
UY29662A1 (es) Nuevos derivados de pirido (3`, 2`: 4, 5) furo (3, 2 -d) pirimidina.
DOP2007000001A (es) Compuestos de heteroarilo biciclicos como inhibidores de pde10
CL2010001557A1 (es) Compuestos derivados de bifenil sustituidos, inhibidores de fosfodiesterasa 10; composicion farmaceutica que los comprende a uno de los compuestos; y uso de la composicion en la preparacion de medicamentos para tratar desordenes neurologicos, neurodegenerativos y siquiatricos.